GlaxoSmithKline has secured rights to 12 drug programs from Jiangsu Hengrui Pharmaceuticals, including the promising phase I COPD candidate HRS-9821, for $500 million upfront and up to $12 billion in potential milestones. The agreement extends GSK’s respiratory portfolio, complementing recent COPD approvals and emphasizing its strategy of integrating innovative Chinese pharma assets. The deal covers global rights except in parts of Greater China and includes collaboration on additional pipelines, positioning GSK to strengthen its presence in immunology and oncology sectors.